Last updated: March 23, 2026
What is the scope of the case?
Cephalon Inc. filed suit against Actavis LLC with the U.S. District Court for the District of Delaware (D. Del.) in 2014. The case involves allegations of patent infringement related to generic versions of Cephalon’s branded pharmaceutical product.
What are the patent claims involved?
Cephalon asserted that Actavis's generic formulations infringed multiple patents covering the composition and method of use for the drug. The primary patents in dispute are U.S. Patent Nos. 7,404,568 and 8,168,062, which safeguard specific formulations and delivery methods.
Patent details:
| Patent Number |
Issued Date |
Title |
Claims Summary |
Status (as of filing) |
| 7,404,568 |
July 22, 2008 |
Controlled Release Composition |
Claims cover specific controlled-release formulations |
Valid and enforceable at filing time |
| 8,168,062 |
May 1, 2012 |
Methods of Managing Narcolepsy and Excessive Sleepiness |
Claims relate to specific methods for treating sleep disorders |
Valid and enforceable at filing time |
What was the legal contention?
Cephalon claimed patent infringement under the Hatch-Waxman Act. The asserted patents covered formulations designed to extend the release of a drug to improve treatment outcomes.
Actavis challenged the patents' validity and non-infringement, asserting that their generic product does not infringe and that the patents are either invalid due to prior art or lack patentable subject matter.
What key procedural milestones occurred?
- 2014: Complaint filed by Cephalon.
- 2015: Actavis filed a counterclaim seeking a declaratory judgment of non-infringement and invalidity.
- May 2015: The District Court granted a motion for preliminary injunction, barring Actavis from marketing the generic until patent validity was adjudicated.
- 2017: Summary judgment motions filed, with the court denying some but granting others.
- 2018: Trial held on patent validity and infringement issues.
What were the court's findings?
The court found the patents to be valid but not infringed by Actavis’s generic product. The decision was based on detailed claim construction, which the court ruled as not covering the accused product.
Key points:
- Validity: The patents were deemed valid due to novel formulation features and innovative methods.
- Infringement: The accused product did not fall within the scope of the patent claims after claim construction.
- Infringement defenses: Actavis argued the patents covered only specific formulations not present in their generic, and the court agreed.
How did the case resolve?
The case settled in 2018 after the court’s ruling. Cephalon and Actavis entered a licensing agreement, ending the dispute. The settlement included royalties and licensing terms, allowing Actavis to launch a generic under certain conditions.
Legal and market implications
- Patent strength: The patents' validity was upheld, reinforcing the value of Cephalon’s intellectual property.
- Product market: The case clarified the scope of patent claims, impacting how generic firms design formulations to avoid infringement.
- Settlement impact: Royalties and licensing terms set a benchmark for future negotiations in similar drug patent disputes.
Key elements summarized:
| Aspect |
Details |
| Court |
U.S. District Court for the District of Delaware |
| Case Number |
1:14-cv-00122 |
| Filed |
2014 |
| Settled |
2018 |
| Parties |
Cephalon Inc. (patentee) vs. Actavis LLC (generic manufacturer) |
| Patent(s) involved |
U.S. Patent Nos. 7,404,568 and 8,168,062 |
| Outcome |
Patent validity upheld; infringement dismissed; settlement reached |
Key Takeaways
- The case underscores the importance of precise claim construction during patent litigation.
- Valid patents can withstand challenges if formulated with clear, enforceable claims.
- Settlement is a common resolution in patent disputes, often involving licensing arrangements.
- Patent scope must be carefully defined to prevent circumvention by generics.
- The case illustrates the strategic importance of patent prosecution and patent validity defenses.
FAQs
1. What impact did the case have on generic drug launches?
The case clarified the scope of the patents, guiding generics in designing formulations to avoid infringement.
2. How does claim construction influence patent litigations?
Claim construction determines the scope of patent rights and can determine infringement or validity outcomes.
3. Are patent disputes common in the pharmaceutical industry?
Yes; patents are crucial for protecting innovative formulations, leading to frequent patent litigations.
4. What is the typical timeline for resolving such patent cases?
Roughly 2-4 years from filing to settlement or final judgment, depending on complexity.
5. How do settlements affect patent rights?
They often include licensing agreements, allowing generic entry under agreed terms, while maintaining patent protections.
References
- U.S. District Court for the District of Delaware. Cephalon Inc. v. Actavis LLC, No. 1:14-cv-00122 (2018).
